Maternal, fetal, and neonatal metabolism of lidocaine
- 1 August 1979
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 26 (2) , 213-220
- https://doi.org/10.1002/cpt1979262213
Abstract
We investigated the metabolism of lidocaine to its active metabolites—monoethylglycinexylidide (MEGX) and glycinexylidide (GX)—in the mother, fetus, and neonate. The study population included normal patients and their infants delivered either vaginally or by cesarean section. A group of infants of mothers in whom pudendal anesthesia was induced was also included. Using gas chromatography and mass spectrometry techniques, the concentrations of lidocaine, MEGX, and GX were determined in maternal plasma during labor, in umbilical cord venous and arterial plasma at delivery, and in maternal and neonatal urine for 3 days post partum. The results indicate the following: In maternal plasma, MEGX rises throughout labor and GX is usually detectable within an hour of medication: in cord blood plasma the levels of lidocaine, MEGX, and GX suggest fetal metabolism of lidocaine; and in neonatal urine, the relative levels of parent compound and metabolites confirm lidocaine metabolism by the neonate.This publication has 2 references indexed in Scilit:
- Quantitation of lidocaine and its deethylated metabolites in plasma and urine by gas chromatography-mass fragmentographyJournal of Chromatography A, 1978
- The pharmacokinetics and metabolism of the anilide local anaesthetics in neonatesEuropean Journal of Clinical Pharmacology, 1978